Annual Congress Copenhagen 2005

Saturday, 17.09.2005
Sunday, 18.09.2005
Monday, 17.09.2005
Tuesday, 20.09.2005
Wednesday, 21.09.2005

Citations should be made in the following way: Authors. Title. Eur Respir J 2005; 26: Suppl. 49, abstract number.

Material from 2005:
  • 4063 Abstracts
  • 739 Slide presentations
  • 213 Webcasts
  • 93 Handouts
Material from 2005:  Show

New strategies and drugs for smoking cessation

Hot topics
Chairs: C. Gratziou (Athens, Greece), L. Allegra (Milano, Italy)
Aims: Tobacco smoking is the most important cause of lung diseases, and smoking cessation is the first and most important therapy to be used in many of the most prevalent among them. Tobacco smoking is a disease in itself; to heal from it is difficult. Failure and relapses are very frequent and, in most smokers, smoking is a chronic condition. There are drugs which can be successfully used for helping smokers to quit: with these drugs the healing is easier even if the long-term success rates remain under 50%. In chest medicine, smoking cessation should always be achieved (in smoking lung patients) and drugs effective in smoking cessation widely prescribed. Smoking cessation and smoking reduction should be included in the routinary clinical practice of every chest physician.
How to predict COPD in a clinical setting
C. Jimenez Ruiz (Madrid, Spain)
Slide presentation
Slide presentation
New drug for smoking cessation: rimonabant
P. Tonnesen (Gentofte, Denmark)
Slide presentation
Slide presentation
New drug for smoking cessation: varenicline
K. Fagerstrom (Helsingborg, Sweden)
Slide presentation
Slide presentation